Plant Huperzine A raw Materials Powder

CAS:102518-79-6

MF:C15H18N2O

MW:242.32

EINECS:242.32

Specification​: 99% min Huperzine A Powder

Sample:Huperzine A Powder

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance:White

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Huperzine A Powder Usage and Synthesis.

Huperzine A is a reversible and potent cholinesterase inhibitor, stronger than physostigmine, neostigmine and Tacrine. For myasthenia gravis, the effective rate is 99%. Clinical trials show that this product is suitable for benign memory disorders, can improve the patients' ability of pointing memory, associative learning, image recall, meaningless figure recognition and portrait recall, and can also enhance the learning and memory of normal people. This product can also improve the memory disorders caused by dementia patients and organic brain lesions. Huperzine A can be used clinically to treat the following symptoms:

1, for the treatment and improvement of middle-aged and elderly memory function decline, improve associative recall function; For memory decline caused by excessive use of the brain, improve learning and work efficiency;

2, for neurasthenia associated with memory decline;

3, huperzine A is used for memory loss caused by cerebrovascular disorders;

4, used to improve the memory of Alzheimer's disease, improve and restore patients' cognition, memory function and improve emotional behavior abnormalities have obvious efficacy;

5, used to treat myasthenia gravis;

6. Huperzine A can improve association disorder, low cognitive function and memory loss associated with schizophrenia.

7, it can improve the memory function decline associated with a variety of brain diseases and physical diseases.

Uses of Huperzine A.

Huperzine A not only inhibits cholinesterase activity, but also affects the free radical system, reduces somatostatin, intracellular [Ca2+], glutamate content, and increases calmodulin (CaM) and calmodulin messenger RNA (CaMmRNA) expression levels and other pharmacological mechanisms to improve cognitive function and learning and memory ability. It can effectively prevent cerebral neurasthenia in middle-aged and elderly people, restore cerebral nerve function, activate cerebral neurotransmitter substances, and is a new drug for the treatment of benign memory disorders.

Effect of Huperzine A.

Huperzine A has selective inhibition on true cholinesterase, and the inhibitory intensity is thousands of times that of false cholinesterase. The inhibition mode was a combination of competitive and non-competitive inhibition, which was significantly different from the single competitive inhibitor. It is easy to enter the center through the blood-brain barrier and has central and peripheral therapeutic effects. Long effective time; Good absorption from gastrointestinal tract; High safety index; Good stability. The inhibitory intensity of different drugs on acetylcholinesterase (AChE) was as follows: huperzine A > physostigmine > Neostigmine > huperzine B > galantamine > galalanin. The inhibitory intensity of human butyryl cholinesterase (BuChE) was as follows: physostigmine > Neostigmine > huperzine A > huperzine B. The effect of this product on strengthening the amplitude of muscle contraction induced by indirect electrical stimulation and enhancing the memory function of rats was stronger than physostigmine, but the toxicity was lower than physostigmine and the action time was longer.

Product Method of Bulk Huperzine A Powder.